SOUTH SAN FRANCISCO, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David Chaplin, Ph.D., CEO, will present a corporate overview at the Rodman and Renshaw Annual Global Investment conference on Tuesday, September 9, 2014 at 1:15 p.m. Eastern Time.
To access the live audio webcast of the presentation, please log on through a link located in the Investors & Media section of OXiGENE's website at www.oxigene.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The Company's lead clinical product candidate, fosbretabulin (also known as ZYBRESTAT), is in development as a potential treatment for solid tumors. OXi4503, its second-generation product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact: firstname.lastname@example.org 650-635-7000